2025-DxkjcU45-05-01)
The battle of the GLP-1 agonists Glucagon-like peptide 1 (GLP-1) agonists, which can be used to treat Type 2 diabetes and for weight management, are a rising class of blockbuster drugs (defined as drugs with sales of $1 billion or more)
The lawsuit asserts that because of this failure Plaintiff was and still is caused to suffer from severe gastrointestinal issues, as well as other severe and personal injuries which are permanent and lasting in nature, physical pain, and mental anguish, including diminished enjoyment of life, as well as the need for lifelong medical treatment, monitoring and/or medications, and fear of developing any of the above-named health consequences. In a statement to CNN for their article Woman sues drug makers of Ozempic and Mounjaro over severe gastrointestinal issues by Jamiel Lynch and Jamie Gumbrecht, Novo Nordisk claimed: Patient safety is of utmost importance to Novo Nordisk
Maybe they have type 2 diabetes or mast cell, which is fatty liver
For dizziness , check blood pressure and a basic metabolic panel for electrolyte imbalances
Diminished GSH synthesis caused by deficiency of its precursors cysteine and glycine is an essential contributor to GSH deficiency